Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02422641 · ClinicalTrials.gov registry record · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
A Phase 2 study of Metastatic Breast Cancer and Leptomeningeal Disease, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 3
- Study locations
NCT02422641 is a Phase 2 study of Metastatic Breast Cancer and Leptomeningeal Disease that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 16 participants, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT02422641, a Phase 2 study of Metastatic Breast Cancer and Leptomeningeal Disease, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is a prospective evaluation of systemic, intravenous high-dose methotrexate (HD-MTX, 8 g/m2) in patients with triple negative, HER2-positive, and hormone refractory breast cancer with leptomeningeal metastasis (LMD) with or without brain parenchymal involvement.
Conditions Studied
Interventions
- DRUG High-dose Methotrexate (8 gm/m2; HD-MTX)
Study Locations (3)
Maryland
- Sidney Kimmel Comprehensive Cancer Center - Baltimore
Missouri
- Siteman Cancer Center- Washington University School of Medicine in St. Louis - St Louis
North Carolina
- Comprehensive Cancer Center at Wake Forest University (CCCWFU) - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-05 |
| Est. Completion | 2027-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02422641
The ClinicalTrials.gov registry entry for NCT02422641 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (92% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which High-dose Methotrexate (8 gm/m2; HD-MTX) is the first listed.
NCT02422641 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Maryland, Missouri, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02422641 about?
NCT02422641 is a clinical study titled "Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis". This study is a prospective evaluation of systemic, intravenous high-dose methotrexate (HD-MTX, 8 g/m2) in patients with triple negative, HER2-positive, and hormone refractory breast cancer with leptomeningeal metastasis (LMD) with or without brain parenchymal involvement.
What is the current status of trial NCT02422641?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2015-05. Estimated completion is 2027-07.
What conditions does trial NCT02422641 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer, Leptomeningeal Disease.
What interventions are being tested in trial NCT02422641?
The interventions under investigation include: High-dose Methotrexate (8 gm/m2; HD-MTX) (DRUG).
Who is sponsoring clinical trial NCT02422641?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02422641 being conducted?
This trial has 3 study locations across Maryland, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
RECRUITING · Phase 2
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
RECRUITING · Phase 2
-
A Study of Surgery and Radiotherapy in People With Breast Cancer
RECRUITING · Phase 2
-
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
RECRUITING · Phase 2
-
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.